136812-31-2 Usage
Uses
Used in Pharmaceutical Synthesis:
7-Bromo-2-chloroquinoline-3-carboxaldehyde is used as a key intermediate in the synthesis of pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
7-BROMO-2-CHLOROQUINOLINE-3-CARBOXALDEHYDE is also utilized in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals that enhance crop protection and yield.
Used in Dye and Pigment Manufacturing:
7-Bromo-2-chloroquinoline-3-carboxaldehyde is employed as a starting material in the manufacturing of dyes and pigments, providing a range of colors for various industrial applications.
Used in Organic Synthesis Research:
As a versatile building block, 7-Bromo-2-chloroquinoline-3-carboxaldehyde is used in organic synthesis research to explore the preparation of novel quinoline derivatives with potential applications in various fields, including materials science and medicinal chemistry.
Used in Medicinal Chemistry Research:
7-BROMO-2-CHLOROQUINOLINE-3-CARBOXALDEHYDE is of interest in medicinal chemistry research due to its potential biological activity. It is studied for its possible applications in the development of new therapeutic agents and understanding its interaction with biological targets.
Check Digit Verification of cas no
The CAS Registry Mumber 136812-31-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,6,8,1 and 2 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 136812-31:
(8*1)+(7*3)+(6*6)+(5*8)+(4*1)+(3*2)+(2*3)+(1*1)=122
122 % 10 = 2
So 136812-31-2 is a valid CAS Registry Number.
InChI:InChI=1/C10H5BrClNO/c11-8-2-1-6-3-7(5-14)10(12)13-9(6)4-8/h1-5H
136812-31-2Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS
-
, (2020/12/11)
The present disclosure describes novel heterocyclic PRMT5 inhibitors and methods for preparing them. The pharmaceutical compositions comprising such PRMT5 inhibitors and methods of using them for treating cancer, infectious diseases, and other PRMT5 associated disorders are also described.
PRMT5 INHIBITORS
-
Page/Page column 76, (2020/03/02)
The present invention provides a compound of Formula (I) Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.
PRMT5 INHIBITORS
-
Page/Page column 108, (2020/03/02)
The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
Enantioselective synthesis of substituted 3-quinolyl alkanols and their application to asymmetric autocatalysis
Sato, Itaru,Nakao, Tomohiko,Sugie, Rie,Kawasaki, Tsuneomi,Soai, Kenso
, p. 1419 - 1428 (2007/10/03)
Enantioenriched 3-quinolyl alkanols act as asymmetric autocatalysts in the addition of diisopropylzinc to the corresponding substituted quinoline-3-carbaldehydes, to afford themselves with an amplified enantiomeric excess (ee) of up to 97%.
